Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zongertinib by Boehringer Ingelheim International for Non-Small Cell Lung Cancer: Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer. According...
Zongertinib by Boehringer Ingelheim International for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase II for Human Epidermal Growth Factor Receptor...
Zongertinib by Boehringer Ingelheim International for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction....
Zongertinib by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase II for Gastric Cancer. According to GlobalData,...
Zongertinib by Boehringer Ingelheim International for Esophageal Cancer: Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Esophageal Cancer. According to GlobalData,...
Zongertinib by Boehringer Ingelheim International for Colorectal Cancer: Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Colorectal Cancer. According to GlobalData,...
Zongertinib by Boehringer Ingelheim International for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According...